Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 257Neoplasms 225Carcinoma, Non-Small-Cell Lung 206Colorectal Neoplasms 148Prostatic Neoplasms 142Lung Neoplasms 116Neoplasm Metastasis 106Ovarian Neoplasms 103Multiple Myeloma 98Pancreatic Neoplasms 89Leukemia, Myeloid, Acute 79Squamous Cell Carcinoma of Head and Neck 75Endometrial Neoplasms 65Melanoma 64Stomach Neoplasms 60Recurrence 59Glioblastoma 57Brain Neoplasms 56Urinary Bladder Neoplasms 51Carcinoma, Hepatocellular 51Triple Negative Breast Neoplasms 50Precursor Cell Lymphoblastic Leukemia-Lymphoma 49Lymphoma 48Head and Neck Neoplasms 47Carcinoma, Renal Cell 46Hematologic Neoplasms 44Esophageal Neoplasms 43Colonic Neoplasms 43Uterine Cervical Neoplasms 42Glioma 42

Interventions

cabozantinib 1Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Urachal adenocarcinoma × 30 days × Clear all
NCT03866382 2026-06-03

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
314 enrolled
Genitourinary

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡